PRTA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
PRTA 近期報酬表現
-3.72%
Prothena corporation plc
4.57%
同產業平均
0.12%
S&P500
與 PRTA 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BIIB | Biogen inc | 5 分 | 4 分 | 4 分 | 3 分 | 1 分 | |
ABOS | Acumen pharmaceuticals inc | - | 3 分 | 4 分 | 2 分 | 1 分 | |
NBTX | Nanobiotix sa - adr | - | 3 分 | 3 分 | 1 分 | 1 分 | |
RCKT | Rocket pharmaceuticals inc | 2 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- BIIB Biogen inc價值 5 分趨勢 4 分波段 4 分籌碼 3 分股利 1 分查看更多
PRTA 公司資訊
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company's pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson's disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer's disease.